Vogliviga GM 0.2/80 Tablet contains Voglibose 0.2mg, Metformin 500mg, and Gliclazide 80mg, offering a comprehensive triple-action therapy for type-2 diabetes mellitus. This formulation helps control blood sugar levels by targeting multiple mechanisms, providing effective glycemic regulation for patients requiring combination therapy.
Voglibose slows carbohydrate absorption in the intestine, Metformin enhances insulin sensitivity and reduces hepatic glucose production, and Gliclazide stimulates pancreatic insulin secretion. Together, they provide balanced control of fasting and postprandial glucose levels, promoting stable metabolic outcomes.
This triple-combination therapy is suitable for patients inadequately managed on dual therapy or monotherapy, offering safety, efficacy, and convenience in a single oral dosage. It is widely used in both outpatient and hospital-based diabetes management programs.
Adding Vogliviga GM 0.2/80 Tablet to your diabetes and metabolic-care portfolio strengthens your product range, unlocking opportunities in retail pharmacy distribution, hospital supply, institutional procurement, export markets, and third-party manufacturing. Its high clinical relevance ensures steady demand and robust commercial performance.